Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-Il-23 Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Subjects

Basic and Clinical Pharmacology and Toxicology - United States
doi 10.1111/bcpt.13001

Related search